Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.

• Status: Unknown status
• Trial end date: 2019-08-29
• Target enrollment: 0
• Participant gender: All

Summary

Ticagrelor has been demonstrated to provide a more rapid and more powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients. However, current guidelines recommend ticagrelor 90 mg twice daily might not be suitable for patients of Chinese. Therefore, the investigators performed this study to observe the efficacy of 60-mg ticagrelor in comparison to 75-mg clopidogrel in Chinese patients with stable CAD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: First Affiliated Hospital of Harbin Medical University
• Treatments: Clopidogrel; Ticagrelor; Ticlopidine

Criteria

Inclusion Criteria:

• Patients were eligible to participate if they were aged ≥18 years and ≤ 75 Years

• Subjects had documented stable CAD (defned as stable angina pectoris and objective evidence of CAD, a previous MI, or previous revascularization with percutaneous coronary intervention or coronary artery bypass grafting)

• Women were required to be postmenopausal or surgically sterile

• Patients who were taking clopidogrel or ticagrelor were required to discontinue these agents at least 14 days before randomization

Exclusion Criteria:

• Acute coronary syndrome (ACS)

• planned use of glycoprotein IIb/IIIa receptor inhibitors, adenosine diphosphate (ADP) receptor antagonists other than the study medication, or anticoagulant therapy during the study period

• platelet count <10*10^4/ul

• creatinine clearance rate < 30ml/min

• diagnosed as respiratory or circulatory instability (cardiac shock, severe congestive heart failure NYHA II-IV or left ventricular ejection fraction < 40%)

• a history of bleeding tendency

• allergy to aspirin, ticagrelor or clopidogrel

• diabetes patients